The aim is to give countries a cheaper and more readily available option to tackle the deadly disease. Developed by Oxford University with the help of the Serum Institute of India, the new vaccine, known as R-21, will be rolled out in some African countries early next year, and expand into other countries later in 2024, according to WHO chief Tedros Adhanom Ghebreyesus. Research that has not yet undergone the usual process of scientific review suggests the three-dose vaccine to be around 75% effective. Boosters would be available for continued protection. The aim of widespread rollout of the vaccine would be to significantly curb infection rates and spread of the disease. However, experts have urged the public not to see vaccines as a replacement for other preventative measures, such as bed nets and the spraying of insecticides.